This study provides a rationale to further investigate which role could play CCL2 expression in MEDU, NFKB1, TNFRSF1A and CCL2 expression in CRBL in the pathogenesis of MS, and eventually to understand why these tissues, are more susceptible to increased expression of these genes also taking into account that the brain displays remarkable cellular heterogeneity even within distinct brain regions. The gene discussed is NFKB1; the disease is myeloid sarcoma.